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It has been described renal damage in rats with vascular calcification. The organic anion transporter 5 (Oat5) is only expressed in
kidney, and its urinary excretion was proposed as potential early biomarker of renal injury.The aim of this study was to evaluate the
Oat5 renal expression and its urinary excretion in an experimental model of vascular calcification in comparison with traditional
markers of renal injury. Vascular calcification was obtained by the administration of an overdose of vitamin D
3
(300,000 IU/kg,
b.w., i.m.) to male Wistar rats. Oat5 urinary abundance was evaluated by Western blotting. Traditional markers of renal injury,
such as creatinine and urea plasma levels, urinary protein levels, and urinary alkaline phosphatase (AP) activity, were determined
using commercial kits. Histology was assessed by hematoxylin/eosin staining. Oat5 renal expression was evaluated by Western
blotting and by immunohistochemistry. An increased expression of Oat5 in renal homogenates, in apical membranes, and in its
urinary excretion was observed in rats with vascular calcification. The traditional parameters used to evaluate renal function were
not modified, with the exception of histology. It is possible to postulate the urinary excretion of Oat5 as a potential noninvasive
biomarker of renal injury associated with vascular calcification.
1. Introduction
Calcium overload in vascular smooth muscle is an active
process which not only progresses with aging but also is
associated with various age-related vascular diseases such as
atherosclerosis, hypertension, and cardiac valve disease [1–3].
An experimental model that produces an increase in arterial
wall calcium content is achieved by the administration of
an overdose of vitamin D
3
[4–8]. In this model, calcium
overload is observed in the arterial wall, in the heart, and in
the kidneys leading to the impairment of their function [2].
Morphological and functional alterations were described in
the kidney [5–8].
Organic anion transporters (Oats in animals/OATs in
humans, subfamily of Slc22 drug transporters)mediate trans-
port of endogenous and exogenous organic anions (OA)
and play a major role in the uptake and/or secretion of OA
in cells of various mammalian organs, mainly in the liver
and in the kidneys. The organic anion transporter type 5
(Oat5, Slc22a19) from rats and mice has been cloned and
characterized as an organic anion/dicarboxylate antiporter
[9–12]. This protein is exclusively expressed in the kid-
neys and is located at the brush border membrane of the
proximal tubule straight segment S3, in the outer stripe of
the outer medulla and in the juxtamedullary cortex [10,
12]. It transports dehydroepiandrosterone sulfate, estrone-3-
sulfate, and ochratoxin A [9–12]. Rat Oat5 interacts with 𝛼-
ketoglutarate, with succinate, and with chemically heteroge-
neous anionic compounds, such as diuretics, nonsteroidal
anti-inflammatory drugs, 𝛽-lactam antibiotics, and bromo-
sulfophthalein [10].
Our group was pioneer in detecting Oat5 in urine and
proposing its urinary excretion as an early indicator of renal
injury [13–15].We have recently described a dramatic urinary
increase of Oat5 in the presence of bilateral mild subclinical
ischemia and bilateral ischemia with acute kidney injury
suggesting that Oat5 might be a potential early noninvasive
marker of this pathology [13]. Moreover, the urinary excre-
tion of Oat5 has also been suggested as an early indicator of
nephrotoxicity induced by mercury and by cisplatin [14, 15].
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The aim of this study was to evaluate Oat5 renal expres-
sion and its urinary excretion in renal damage associated
with vascular calcification in comparison with traditional
markers of renal injury, such as histology, creatinine and urea
plasma levels, urinary protein levels, and urinary alkaline
phosphatase (AP) activity.
2. Materials and Methods
2.1. Experimental Animals. Adult male Wistar rats (310–
360 g; aged 110–130 days) were used. Animals had free access
to a standard laboratory chow and tap water and were
housed in a constant temperature and humidity environment
with regular light cycles (12 h) during the experiment. All
experiments were conducted according to NIH Guide for the
Care andUse of Laboratory Animals. For surgical procedures
rats were anesthetized with sodium thiopental (70mg/kg,
b.w., i.p.).
Animals were randomly divided into two groups: control
and treated rats. Treated rats were injected with a single over-
dose of vitamin D
3
(300,000 IU/kg, b.w., i.m.) 10 days before
the experiments in order to achieve an experimentalmodel of
vascular calcification as previously described [2, 4–8]. Vita-
min D
3
solutions were prepared in corn oil. Control animals
received an identical volume of corn oil by i.m. injection
(1mL/kg). The diagram of study design is shown in Figure 1.
Two different sets of experimental animals were em-
ployed.
(i) One set of rats was used for histopathological and
immunohistochemical studies in kidneys and histo-
chemical calcium assay in abdominal aorta (𝑛 = 4 for
each experimental group).
(ii) Another set of animals was used for measurement of
arterial pressures. Then, the rats were anesthetized as
previously described, blood was collected from the
heart in heparinized syringe, and urine was collected
from the urinary bladder with a syringe immediately
after opening the abdominal cavity. Urine samples
were obtained for biochemical assays and for detec-
tion of Oat5 by Western blotting, and blood samples
were used for biochemical parameters assays (𝑛 =
4 for each experimental group). Finally, kidneys
were removed for preparation of homogenates and
apical membranes for Western blotting studies, and
abdominal aorta was extracted for analyzing tissue
calcium levels (𝑛 = 4 for each experimental group).
2.2. Measurement of Arterial Pressure. Systolic and mean
arterial pressure were measured in both control (𝑛 = 4) and
treated rats (𝑛 = 4) with a Harvard indirect rat tail blood
pressure monitor (Harvard Apparatus, Millis, MA, USA)
connected to a Harvard student oscillograph, as previously
described [5–8].
2.3. Vascular Calcium Analysis. Calcium levels in abdominal
aorta were evaluated by a spectrophotometric technique
and by histochemistry employing von Kossa staining. For
spectrophotometric studies abdominal aorta was removed,
weighed, and then heated to constant dry weight for 48 h at
120∘C. Dry samples were dissolved in nitric acid (14mol/L)
and left for 72 h at room temperature. Samples were then cen-
trifuged (2000×g, 10min, and at room temperature). Stron-
tium nitrate was added and calcium was measured by atomic
absorption spectrophotometry, as described by Quaglia et al.
[5–7]. For calcification studies using von Kossa method,
abdominal aorta was dissected and rinsed in saline solu-
tion and immersed in periodate-lysine-paraformaldehyde
solution (0.01M NaIO
4
, 0.075M lysine, and 0.0375M phos-
phate buffer, with 2% paraformaldehyde, pH: 6.20), at 4∘C
overnight.Then, the tissuewas embedded in paraffin. Paraffin
sections were cut. After deparaffining, the sections were
hydrated and exposed to 5% silver nitrate under ultraviolet
light for 60min. After washing in 5% sodium hyposulfite for
3min, the sections were counterstained with 0.01% nuclear
fast red for 5min and examined under a light microscope
similar to that previously described by Han et al. [16].
2.4. Biochemical Determinations. Urine samples (centrifuged
at 1000×g for 10min to remove cell debris) were used for
analyses of AP activity, proteins concentration, and creatinine
concentration. Blood was extracted by cardiac puncture, and
blood plasma was separated by centrifugation (1000×g for
10min).These samples were used to assay calcium levels, urea
concentration, and creatinine concentration.
All parameters were determined spectrophotometrically
using commercial reagent kits (Wiener Laboratory, Rosario,
Argentina).
2.5. Histopathological Studies. Histopathology of kidneys was
performed after fixing them in 10% neutral buffered
formaldehyde solution for 4 h and embedding them in
paraffin.Then 4𝜇m thick sections were processed for routine
staining with hematoxylin and eosin.
2.6.Immunohistochemistry.The immunohistochemistry tech-
nique was performed as previously described [13–15]. Kid-
neys from both experimental groups of rats were brief-ly
perfused with saline, followed by perfusion with perio-date-
lysine-paraformaldehyde solution (0.01M NaIO
4
, 0.075M
lysine, and 0.0375M phosphate buffer, with 2% parafor-mal-
dehyde, pH 6.20), through a cannula inserted in the abdom-
inal aorta. Kidney slices were immersed in periodate-lysine-
paraformaldehyde solution at 4∘C overnight. The tissue
was embedded in paraffin. Paraffin sections were cut. After
deparaffining, the sections were incubated with 3% H
2
O
2
for 15min (to eliminate endogenous peroxidase activity) and
then with blocking serum for 30min. These sections were
then incubated with noncommercial polyclonal antibody
against Oat5 (diluted 1 : 100) overnight at 4∘C. The specificity
of Oat5 antibody has been described elsewhere [10]. The
sections were rinsed with PBST. Then, the sections were
incubated with horseradish peroxidase- (HRP-) conjugated
secondary antibody against rabbit immunoglobulin for 1 h. In
order to detect HRP labeling a peroxidase substrate solution
with diaminobenzidine (0.05% diaminobenzidine in PBST
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Figure 1: Diagram of study design. Animals were randomly divided into two groups: control and treated rats. Treated rats were injected
with a single overdose of vitamin D
3
(300,000 IU/kg, b.w., i.m.) 10 days before the experiments in order to achieve an experimental model
of vascular calcification as previously described [4–7]. Vitamin D
3
solutions were prepared in corn oil. Control animals received an identical
volume of corn oil by i.m. injection (1mL/kg).
(80mM Na
2
HPO
4
, 20mM NaH
2
PO
4
, 100mM NaCl, and
0.1% Tween 20, pH 7.50) with 0.05% H
2
O
2
) was used. The
sections were counterstained with hematoxylin before being
examined under a light microscope.
Controls using preimmune serum and antiserum ab-
sorbed with excess synthetic peptide or omission of primary
or secondary antibody revealed no labeling.
2.7. Preparation of Apical Membranes from Kidney. Apical
membranes were isolated from kidneys by Mg/EGTA pre-
cipitation as previously described [13–15]. The kidneys were
removed, minced, and homogenized in 30 g/100mL of ice-
cold 50mMmannitol, 2mMTris HCl buffer (pH 7.10), 5mM
EGTA, and 1mM PMSF for 5min at top speed in a Glas-
Col homogenizer. From this preparation we obtained total
homogenates, and aliquots were taken and stored at −80∘C
until use.
Then, MgCl
2
was added to the remaining homogenate to
a final concentration of 12mM, and themixture was stirred in
an ice bath for 15min. The homogenate was then centrifuged
(3000×g, 15min, and 4∘C). The supernatant was carefully
decanted and centrifuged again at 28,000×g for 40min at
4∘C. The pelleted material representing brush border mem-
branes was resuspended in 50mMmannitol, 10mMHEPES-
Tris (pH 7.50), and 1mM PMSF and centrifuged for 15min
at 800×g at 4∘C. The supernatant was finally centrifuged for
45min at 28,000×g. The brush border membranes pellets
thus obtained were resuspended in 50mM mannitol, 10mM
HEPES-Tris buffer (pH 7.40), and 1mM PMSF. Aliquots of
the membranes were stored immediately at −80∘C. Each
preparation represented renal tissues from four animals. The
enrichment and purity of these membranes were comparable
to those previously reported [13–15]. Protein quantification
of samples was performed using the method of Sedmak and
Grossberg [17].
2.8. Electrophoresis and Immunoblotting.Homogenates (35 𝜇g
of protein), apical membranes (25𝜇g of protein), and urine
(10 𝜇L) samples were boiled for 3min in the presence of
1% 2-mercaptoethanol/2% SDS. Samples were applied to
an 8.5% polyacrylamide gel, separated by SDS-PAGE, and
electroblotted to nitrocellulose membranes. To verify equal
protein loading and transfer between lanes, Ponceau Red
was used as previously described [14, 15, 18]. The nitro-
cellulose membranes were incubated with 5% nonfat dry
milk in PBST for 2 h. After being rinsed with PBST, the
membranes were incubated overnight at 4∘C with a rabbit
polyclonal antibody against rat Oat5 (at a dilution of 1 : 800).
The specificity of Oat5 antibody has been described else-
where [10]. The membranes were incubated for 1 h with a
peroxidase-coupled goat anti-rabbit IgG (Bio-Rad; Hercules,
CA) after further washing with PBST. Blots were processed
for detection using commercial kit (Pierce ECL Western
Blotting Substrate; Thermo Scientific, Rockford, IL, USA). A
densitometric quantification of the Western blotting signal
intensity of membranes was performed. For densitometry of
immunoblots, samples from treated rat kidneys were run on
each gel with corresponding control kidneys. The abundance
of Oat5 in the samples from treated animals was calculated as
percentage of the mean value of control rats for that gel.
2.9. Materials. Chemicals were purchased from Sigma (St.
Louis, MO) and were of pure analytical grade.The polyclonal
antibody against Oat5 employed in both immunohistochem-
istry and immunoblotting technique was courteously given
by Professor H. Endou and Professor N. Anzai (Department
of Pharmacology and Toxicology, Kyorin University School
of Medicine, Tokyo, Japan).
2.10. Statistical Analysis. The statistical analysis was per-
formed using the unpaired Student 𝑡-test. When variances
were not homogeneous, Welch’s correction was employed.
𝑃 < 0.05 was considered statistically significant. Data
are expressed as means ± standard error (SEM). For these
analyses, GraphPad software was used.
3. Results
As it is shown in Table 1, systolic arterial pressure (SAP) and
mean arterial pressure (MAP) were increased in rats treated
with vitamin D
3
. In contrast, body weight, kidney weight,
and its ratio were not modified with the treatment. Plasma
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Figure 2: Determination of calcium load in abdominal aorta from control (a) and treated (b) rats. These pictures are representatives of
samples obtained from four animals from each experimental group. Sections were stained according to the von Kossa method. von Kossa
staining demonstrated the absence of calcification in control blood vessel whereas treated ones showed calcification. Calcified nodules are
marked with arrows. M indicates media; Ad indicates adventitia. Bars: 40𝜇m.
Table 1: Systolic arterial pressure (SAP), mean arterial pressure
(MAP), body weight, kidney weight, renal/body weight, total cal-
cium in plasma, urea levels in plasma, creatinine levels in plasma,
and total calcium levels in aorta in control and treated (vitamin D
3
300,000 IU/kg, b.w, i.m) rats.
Control (𝑛 = 4) Treated (𝑛 = 4)
SAP (mmHg) 100 ± 5 140 ± 8∗
MAP (mmHg) 55 ± 3 76 ± 4∗
Body weight (g) 363 ± 10 363 ± 3
Kidney weight (g) 2.61 ± 0.11 2.45 ± 0.05
Renal/body weight 0.0072 ± 0.0002 0.0068 ± 0.0001
Plasma calcium (mg/dL) 9.4 ± 0.4 9.8 ± 0.7
Plasma urea (g/L) 0.48 ± 0.06 0.53 ± 0.06
Plasma creatinine (mg/L) 6.2 ± 0.5 6.8 ± 0.8
Total calcium levels in aorta
(𝜇mol/g dry weight) 20 ± 3 50 ± 4
∗
Results are expressed as mean values ± SEM.
∗
𝑃 < 0.05.
calcium, urea, and creatinine levels did not change in treated
rats when compared with control ones. Total calcium levels
(𝜇mol/g dry weight) were significantly increased in aorta
from treated animals.
Areas of medial calcification were detected in von Kossa-
stained sections as deposits of brown-blackmaterial in aortas
from rats with vascular calcification (Figure 2).
Histopathological studies assessed by hematoxylin/eosin
staining revealed tubular alterations with vacuoles in the
cytoplasm, glomeruli of reduced size, and no morphological
changes in the interstitium of kidneys from rats with vascular
calcium overload (Figure 3). These modifications are consis-
tent with those previously described for this experimental
model [4, 7, 8].
Other traditional parameters of renal function as total
proteins and AP activity in urine were evaluated. Total
proteins in urine related to urinary creatinine levels were
not modified with the vitamin D
3
treatment as shown in
Figure 4(a). AP activity in urine (also normalized to urinary
creatinine concentration) was not changed in the treated
group compared with the control group (Figure 4(b)).
The concentration of proteins and AP activity in urine
were related to urinary concentration of creatinine in order to
correct variations in urine production as previously described
for total proteins, transporters, and enzymes [13–15, 19–
23]. Normal physiological variations in urinary water excre-
tion can dilute or concentrate such proteins, transporters,
and enzymes; therefore individual measurements of these
parameters are insufficient. Creatinine is excreted in urine at
relatively constant rates; hence it can be used to normalize
urinary excretion of a particular parameter. Oat5 abundance
in urine was also related to urinary creatinine concentration
as described above. Figure 4(c) shows that Oat5 abundance
in urine samples was significantly higher in rats that received
vitamin D
3
.
As shown in Figure 5, there was a significant increase in
Oat5 abundance in homogenates and in apical membranes
from vitamin D
3
treated rats compared to those from control
animals.
Immunohistochemistry studies revealed Oat5 labeling
associated with the apical membrane domain in proximal
tubule cells as previously described [10, 13–15]. In vitamin
D
3
treated animals a strong increase in Oat5 labeling was
observed (Figure 6). These results corroborated the data
obtained by Western blotting.
4. Discussion
Even if, in the last years, several breakthroughs in the
knowledge of renal pathologies have been made, these have
not been successful regarding the decrease of high rates of
mortality associated with them. The lack of safe and reliable
markers to detect diseases on their onset delays the start of a
treatment [24, 25].
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Figure 3: Optical microscopy photos of kidney histology from control and treated (vitamin D
3
300,000 IU/kg, b.w., i.m.) animals. These
pictures are representatives of samples obtained from four animals from each experimental group. Renal histological studies revealed tubular
alteration with vacuoles in the cytoplasm (arrows), glomeruli of reduced size (asterisks) in kidneys from rats with vascular calcium overload.
Bars: 40𝜇m.
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Figure 4: Total protein levels (a), alkaline phosphatase (AP) activity (b), and Oat5 abundance (c) in urine from control (𝑛 = 4) and treated
(vitamin D
3
300,000 IU/kg, b.w., i.m., 𝑛 = 4) animals. Total urine protein levels and AP urinary activity were determined using commercial
kits and related to urinary creatinine concentrations to correct them for variations in urine production. Oat5 abundance was determined
by Western blotting using a noncommercial antibody as described in Section 2. Densitometric quantification of Oat5 immunoblotting from
urine is expressed as arbitrary units also related to urinary creatinine concentrations, and the mean of the control levels was set as 100%.
Results are expressed as mean values ± SEM. ∗𝑃 < 0.05.
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Figure 5:Oat5 abundance in renal homogenates (a) and apicalmembranes (b) fromkidneys of control and treated (vitaminD
3
300,000 IU/kg,
b.w., i.m.) rats. Proteins were separated by SDS-PAGE and blotted onto nitrocellulosemembranes. Oat5 was identified using a noncommercial
antibody as described in Section 2.Themean of the control levels was set as 100%. Each column represents themean ± SEM from experiments
carried out in four animals for each experimental group. ∗𝑃 < 0.05.
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Figure 6: Immunohistochemistry for Oat5 in kidneys from control and treated (vitaminD
3
300,000 IU/kg, b.w., i.m.) animals. Serial sections
from each rat kidney were stained using a noncommercial anti-Oat5 antibody. In kidneys from treated group a marked increase in the Oat5
staining was observed. These figures are representatives of typical samples from four rats for each experimental group. Bars: 40𝜇m.
A biomarker can be defined as any plausible parameter
being objectively evaluated in a patient as an indicator
of normal biological, pathologic, or therapeutic response
processes. A biological marker should have the following
ideal characteristics: easily measurable on an accessible fluid,
stability in the said fluid, detectable on early stages before the
traditional kidney injury markers that are modified, being
a specific injury marker of certain area of the kidney, and
having the value to predict its evolution [26, 27].
Low molecular weight proteins, enzymes, urinary anti-
gens, and transporters, which have been detected in urine in
early stages of kidney damage, have been used as biomarkers
of renal disease [28–30]. Regarding transporters, we can
mention that aquaporin 2 has been detected in rat and human
urine and it has been used as a marker for different patholo-
gies [31, 32] and that isoform 3 of the Na+-H+ exchanger
NHE3 has been proposed as acute renal failure marker [33].
Organic anion transporter type 5 (Oat5/OAT5) has been
studied in rat, mouse, and human organs, but the available
data indicate that the rodent and human genes are not
orthologs and code for different proteins. Oat5 was first
isolated from a mouse cDNA library in 2004 [9]. Subse-
quently, Oat5 was cloned from a rat kidney cDNA library
[10]. Human OAT5 was cloned in 2001 [34]. However, no
functional data has yet been obtained for the hOAT5 clone,
and it is now believed that it is not the human orthologue of
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the rodent Oat5s. Thus, the rodent and human forms have
been assigned different names within the SLC22A family,
with the human form retaining its SLC22A10 systematic name
and the rodent Oat5s being designated Slc22a19 [9–12, 34–
37]. In rats and mice the Northern blotting and RT-PCR
studies showed the presence of Oat5 (Slc22a19) mRNA only
in the kidney [9–12], whereas in humans OAT5 (SLC22A10)
mRNA was located by Northern blotting exclusively in the
liver [34, 35]. Oat5 from mice (mOat5) and rats (rOat5)
have been characterized, being at the level of cDNA and
peptide sequences identical to 88% and 82%, respectively.
rOat5 protein exhibits limited identity to hOAT4 (47%),
rOat1 (39%), rOat2 (37%), and rOat3 (37%) proteins [9, 10].
mOat5 was identified as the 85 kDa protein band by Western
blotting of renal brush border membrane [12], whereas in
the rOat5-transfected HEK293 cells and in renal total cell
membranes the protein showed up as the 65 kDa and 72 kDa
bands, respectively [10, 38]. rOat5 mRNA was localized to
the proximal tubule S2 and S3 segments (S2 < S3) in isolated
tubules by RT-PCR [10]. By immunohistochemistry of the
rat and mouse kidneys, the transporter was detected in the
brush border membrane of proximal tubule straight segment
(S3) [10, 12]. Oat5 has been defined as a probenecid-sensitive
organic anion/dicarboxylate exchanger, which can transport
ochratoxin A, dehydroepiandrosterone sulfate, and estrone-
3-sulfate and be inhibited by bumetanide, furosemide, peni-
cillin G, sulfobromophthalein, and by some sulfate but
not glucuronide conjugates [10]. Moreover, mOat5, but not
rOat5, was found to transport salicylate, but none showed a
significant affinity for p-aminohippurate [9–12]. Breljak et al.
[38] have recently described that renal expression of Oat5 in
rats and mice exhibits the female-dominant sex differences.
Studies carried out in our laboratory have shown modifi-
cations in the abundance of Oat5 protein in homogenates
and in apical membranes from total renal tissue in different
models of renal injury [13–15]. Moreover, our group has been
pioneer in the detection of Oat5 in urine [13].This allowed us
to evaluate Oat5 renal excretion in the presence of different
levels of renal damage, associated with different periods of
ischemia and renal reperfusion and with the induction of
nephrotoxicity by using different doses of mercuric chloride
or cisplatin. In these studies it was observed that Oat5 renal
excretion is increased evenwhen there were no changes in the
conventionally used biomarkers of renal injury as uraemia,
creatininemia, and urinary AP activity [13–15]. Therefore,
Oat5 renal excretion has been proposed as a biomarker for
early renal damage.
It is important to make a reference about the utility of
renal damage traditional biomarkers in this work: the urea is
the main nitrogenous waste product of proteins metabolism.
It is synthesized in the liver and excreted at renal level through
glomerular filtration with variable absorption and secretion.
Its increase in blood could be caused by an acute or chronic
renal failure or a decrease of renal perfusion. Although
plasma urea is a frequent parameter used in the assessment
of renal function, it is low sensitive and only rises when more
than a half of renal function is lost, and it is not very specific.
It can also rise in blood due to other factors such as an
important increase of protein contribution or an important
increase of protein catabolism. Creatinine is a product of
protein metabolism which is derived from creatine. Creatine
is stored in themuscle as creatine and phosphocreatine before
being metabolized and released to circulation as creatinine.
Creatinine is eliminated by glomerular filtration, it is not
reabsorbed, and its tubular secretion is minimal. Validity
of creatinine as a proof of renal function is based on the
premise that, in a normal individual in stable conditions, as
creatinine is released from muscular deposits at a constant
rate during the day, its accumulation in the body is prevented
by a renal excretionmechanism.Themost important cause of
the increase of thismetabolite in plasma is an alteration of the
glomerular filtration. Nevertheless, it may also rise through
an elevated pathologic muscular change or in individuals
with an elevated muscle mass [39]. In a normal kidney only
a small quantity of low molecular weight proteins filtrates
and most of them are reabsorbed in tubules. The presence
of high amounts of proteins in urine could be a sign of
an important renal disease, even preceding other symptoms
[19, 20]. Nevertheless benign proteinuria could appear in case
of fever, cold exposure, intense physical work, and so forth.
AP is an enzyme expressed in the apical membrane of tubular
cells, with predominance on the brush border of the proximal
tubule cells [40]. An increase of urinary excretion of this
protein involves damage in brush bordermembrane with loss
of microvilli structure [41]. Histopathological studies are well
known for them usefulness in the diagnosis of kidney and
other organs diseases, but they have the disadvantage of being
invasive methods, which complicates their use especially on
humans.
After having described that the increase of Oat5 in
urinary excretion, in renal failure models studied [13–15],
precedes modifications on the traditional parameters previ-
ously mentioned, we wonder if Oat5 renal excretion would
be modified in pathologies of nonrenal origin but associated
with some type of renal nephropathy.Therefore, the objective
of this work was to evaluate the Oat5 urinary excretion
and its renal expression in a model of vascular calcification,
which according to our laboratory shows a decrease in the
glomerular filtration rate, with tubular damages, histological
alterations and without modifications on the uraemia [4–
8]. Oat5 urinary excretion in this model was compared with
other traditional markers of renal damage such as creati-
nine in plasma, proteins in urine, and alkaline phosphatase
activity in urine. None of these parameters were modified
in this vascular calcification model. On the contrary, Oat5
urinary excretion, evaluated by Western blotting technique
and normalized with the concentration of creatinine in urine,
was increased by 111%. The initial centrifugation of urine
allowed us to affirm that urinary Oat5 was not due to the
presence of tubular cells from cellular shedding. To evaluate
the origin of urinary Oat5, its renal expression was evaluated
by immunohistochemistry studies and Western blotting in
total homogenates and apical membranes.
An increase of Oat5 abundance both in homogenates and
apical membranes from renal tissue of animals with vascular
calcification was observed. The increase of Oat5 protein in
homogenates could indicate an increase in the synthesis of
this protein or a decrease of its degradation.
8 BioMed Research International
In this experimental model of vascular calcification
we have described modifications in the renal transporters
expression.The abundance of theNa+-K+-2Cl− cotransporter
(NKCC2) showed an increase in renal medulla homogenates
and did not change in renal cortex homogenates [7]. On
the other side, Oat1 protein revealed a decrease in its
expression in renal cortex homogenates [8]. Heterogeneous
changes observed in NKCC2, Oat1, and Oat5 expression in
homogenates of renal tissue in animals with this pathology
underscore the selectivity of the response.
The fact that the understudy protein also increases in
apical membrane, but the relation between Oat5 abundance
in apical membranes and homogenates has a value less than
unity, suggests a diminished traffic of the protein to the
membrane or an increase of its release towards tubular lumen.
The increase of Oat5 excretion in urine would be in favour of
the latter hypothesis.
It is known that calcium has an important role in
numerous cellular functions [42]. Changes in themetabolism
of renal calcium generated, in this model, by vitamin D
3
overdose [43] could cause the activation of several pathways
of intracellular signaling aimed to modify the synthesis
and/or degradation of Oat5 protein, its traffic to the apical
membrane, and its urinary excretion. It is important to
note that until date the cellular mechanisms of physiological
regulation of Oat5 are unknown.
Hence, the preclinical animal results showed in this work
in addition to the data presented before by our group [13–
15] propose that Oat5 urinary excretion might potentially
serve as a noninvasive early biomarker of mercury, cisplatin,
ischemic, and vascular calcification which induced renal
damage. Efforts to identify biomarkers to assist in early
diagnosis of renal damage have yielded many promising
candidates. To date, most studies have emphasized discovery,
characterization, and validation of individual biomarkers
using a single experimental model of kidney injury. This
approach is necessary in the initial stages of biomarker devel-
opment; however, translation to general clinical applicability
requires considerable additional work [44].
As it was previously described, Oat5 was discovered by
in silico analysis of the Ensembl mouse genome database
[9]. Although orthologs have been identified in both mice
and rats (Slc22a19), Vanwert et al. [37] have postulated the
importance of discovering a human orthologue for rodents
Oat5. Rat Oat5 has been proposed to act like human OAT4
(hOAT4, SLC22A11) since both transporters share some com-
mon characteristics. For example, hOAT4 is also localized
to the proximal tubule brush border membranes and also
transports ochratoxin A, dehydroepiandrosterone sulfate,
estrone-3-sulfate, and various others organic anions [10, 36,
37]. Nevertheless, rOat5 shows a remote amino acid sequence
similarity to hOAT4 (47%); rOat5 is expressed mainly in
the late segments (S2 and S3) of proximal tubules whereas
hOAT4 is expressed throughout the proximal tubules (from
S1 to S3); rOat5 does not transport p-aminohippurate (PAH,
a prototypical substrate for renal organic anion transport)
while hOAT4 transports PAH [10]. At this point, it is
important to mention that preliminary studies carried out
in our laboratory detected one band with rOat5 antibodies
in urine samples from four adult healthy humans with
identical molecular weight to that observed in rat urine
(M. S. Trebucobich, M. H. Hazelhoff, and R. P. Bulacio; A.
Brandoni, and A. M. Torres, unpublished data, 2013). Current
experiments are performed in our laboratory in order to
characterize the nature of the protein detected in human
urine with anti-rOat5 antibodies.
5. Conclusion
The results obtained in this work indicate that Oat5 urinary
excretion in the studied pathology is increased in the absence
of modifications of traditional parameters to evaluate the
renal function like urea in plasma, creatinine in plasma,
proteins in urine, and AP activity in urine. However, the
increase in urinary excretion of Oat5 carrier would occur in
conjunctionwith histological alterations andmodifications in
hemodynamic as well as tubular renal functions as previously
described [7]. These last parameters have to be evaluated
through the use of invasive methodologies, unlike Oat5 uri-
nary determination. So, it is possible to postulate the urinary
excretion of Oat5 as a potential noninvasive biomarker of
renal damage associated with vascular calcification.
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